Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04462198 · ClinicalTrials.gov registry record · Phase 1
Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss
A Phase 1 study, sponsored by Contineum Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT04462198 is a Phase 1 study that has completed, run by Contineum Therapeutics. The registered enrollment target is 28 participants.
The verdict
NCT04462198, a Phase 1 study, has completed, sponsored by Contineum Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a randomized, double-blind study of PIPE-505, or placebo, in subjects with hearing loss associated with speech-in-noise impairment.
Interventions
- DRUG Placebo
- DRUG PIPE-505
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2021-06-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04462198
The ClinicalTrials.gov registry entry for NCT04462198 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Contineum Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04462198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04462198 about?
NCT04462198 is a clinical study titled "Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss". This is a randomized, double-blind study of PIPE-505, or placebo, in subjects with hearing loss associated with speech-in-noise impairment.
What is the current status of trial NCT04462198?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2020-10-15. Estimated completion is 2021-06-17.
What interventions are being tested in trial NCT04462198?
The interventions under investigation include: Placebo (DRUG), PIPE-505 (DRUG).
Who is sponsoring clinical trial NCT04462198?
This trial is sponsored by Contineum Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.